Roy-Vallejo, EmiliaSanchez-Purificacion, AquilinoTorres-Peña, Jose DavidSanchez-Moreno, BeatrizArnalich, FranciscoGarcia-Blanco, Maria JoseLopez-Miranda, JoseRomero-Cabrera, Juan LuisHerrero Gil, Carmen RosarioBascunana, JoseRubio-Rivas, ManuelPintos-Otero, SaraMartinez-Sempere, VeronicaBallano-Rodriguez-Solis, JesusGil-Sanchez, RicardoLuque-Del-Pino, JairoGonzalez-Noya, AmaraNavas-Alcantara, Maria SierraCortes-Rodriguez, BegoñaAlcala, Jose NicolasSuarez-Lombraña, AnaAndres-Soler, JorgeGomez-Huelgas, RicardoCasas-Rojo, Jose ManuelMillan-Nuñez-Cortes, Jesus2023-02-092023-02-092021-06-11Roy-Vallejo E, Sánchez Purificación A, Torres Peña JD, Sánchez Moreno B, Arnalich F, García Blanco MJ, et al. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Withdrawal Is Associated with Higher Mortality in Hospitalized Patients with COVID-19. J Clin Med. 2021 Jun 15;10(12):2642.2077-0383http://hdl.handle.net/10668/18098Our main aim was to describe the effect on the severity of ACEI (angiotensin-converting enzyme inhibitor) and ARB (angiotensin II receptor blocker) during COVID-19 hospitalization. A retrospective, observational, multicenter study evaluating hospitalized patients with COVID-19 treated with ACEI/ARB. The primary endpoint was the incidence of the composite outcome of prognosis (IMV (invasive mechanical ventilation), NIMV (non-invasive mechanical ventilation), ICU admission (intensive care unit), and/or all-cause mortality). We evaluated both outcomes in patients whose treatment with ACEI/ARB was continued or withdrawn. Between February and June 2020, 11,205 patients were included, mean age 67 years (SD = 16.3) and 43.1% female; 2162 patients received ACEI/ARB treatment. ACEI/ARB treatment showed lower all-cause mortality (p < 0.0001). Hypertensive patients in the ACEI/ARB group had better results in IMV, ICU admission, and the composite outcome of prognosis (p < 0.0001 for all). No differences were found in the incidence of major adverse cardiovascular events. Patients previously treated with ACEI/ARB continuing treatment during hospitalization had a lower incidence of the composite outcome of prognosis than those whose treatment was withdrawn (RR 0.67, 95%CI 0.63–0.76). ARB was associated with better survival than ACEI (HR 0.77, 95%CI 0.62–0.96). ACEI/ARB treatment during COVID-19 hospitalization was associated with protection on mortality. The benefits were greater in hypertensive, those who continued treatment, and those taking ARB.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/ACEIARBCOVID-19MACEprognosisHumansFemaleAgedAngiotensin Receptor AntagonistsRetrospective StudiesAngiotensin-Converting Enzyme InhibitorsIncidenceRespiration, ArtificialCOVID-19HypertensionPrognosisHospitalizationAngiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Withdrawal Is Associated with Higher Mortality in Hospitalized Patients with COVID-19.research article34204014open accessAncianoAntagonistas de receptores de angiotensinaEstudios retrospectivosFemeninoHipertensiónHospitalizaciónIncidenciaInhibidores de la enzimaConvertidora de angiotensinaPronósticoRespiración artificial10.3390/jcm10122642PMC8232748https://www.mdpi.com/2077-0383/10/12/2642/pdf?version=1623981900https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232748/pdf